REVIEW article
Front. Oncol.
Sec. Molecular and Cellular Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1596541
This article is part of the Research TopicNational Cancer Research Month 2025: Advances in Detection, Treatment and Therapies in OncologyView all 9 articles
Advances in Research on RNA Methylation and Cancer Radiotherapy Resistance
Provisionally accepted
- 1Ningbo Medical Centre Lihuili Hospital, Ningbo, China
- 2Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
RNA methylation is a type of reversible chemical modification in epitranscriptomics that influences gene expression by dynamically regulating RNA functions. RNA methylation comprises N6-methyladenosine (m6A), 5-methylcytosine (m5C), N7-methylguanosine (m7G), N1-methyladenosine (m1A), and 3-methylcytosine (m3C) modifications. These are dynamically controlled by a tripartite enzymatic system: methyltransferases ("writers") add methyl groups, demethylases ("erasers") remove them, and RNA-binding proteins ("readers") recognize and interpret the modifications to mediate downstream biological effects. Extensive research has shown the importance of RNA methylation in the onset and progression of cancer. RNA methylation contributes to radioresistance in cancer cells through various mechanisms, affecting therapeutic outcomes. To date, the precise functions of RNA methylation in cancer radioresistance remain unclear. This review summarizes recent advances in m6A, m5C, m7G, and m1A methylation in cancer radioresistance regulation and discusses the clinical potential of precision therapeutic strategies targeting these methylation modifications.
Keywords: ：m6A methylation, m5C methylation, m7G methylation, m1A methylation, radioresistance
Received: 21 Mar 2025; Accepted: 19 Jul 2025.
Copyright: © 2025 Liu, Luo, Jin, Zheng, Xi and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Kaitai Liu, Ningbo Medical Centre Lihuili Hospital, Ningbo, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.